Health & Beauty Technologies, Inc et al v. Merz Pharma GmbH KgaA et al

Filing 250

ORDER - Plaintiffs' motion to amend or alter the judgment 241 is GRANTED IN PART and DENIED IN PART. The court VACATES its judgment and DIRECTS the clerk to reopen this case. Plaintiffs' claim for unjust enrichment is ALLOWED to proceed to discovery. Plaintiffs' remaining causes of action are DISMISSED. Defendants' motion for bill of costs 237 is DENIED AS MOOT. The court's initial order on planning and scheduling will follow. Signed by District Judge Louise Wood Flanagan on 1/8/2020. (Collins, S.)

IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF NORTH CAROLINA
SOUTHERN DIVISION
NO. 7:18-CV-117-FL
HEALTH & BEAUTY
TECHNOLOGIES, INC.; and MEDIBUILD INTERNATIONAL, CORP.,
Plaintiffs,
v.
MERZ PHARMA GMBH KGAA; and
MERZ NORTH AMERICA, INC.,
Defendants.

)
)
)
)
)
)
)
)
)
)
)
)

ORDER

This matter comes before the court on plaintiffs’ motion to amend or alter the judgment,
pursuant to Federal Rule of Civil Procedure 59(e). (DE 241). The issues raised have been fully
briefed, and in this posture are ripe for ruling. For the reasons that follow, plaintiffs’ motion is
granted in part and denied in part.
STATEMENT OF THE CASE
Plaintiffs initiated this action on June 26, 2017, in the United States District Court for the
Southern District of Florida, alleging they are owed compensation for providing defendants with
certain confidential and proprietary analysis on acquisition targets in or around December 6, 2013.
On March 23, 2018, the Southern District of Florida found that it lacked personal jurisdiction over
defendants but transferred the case to this district pursuant to 28 U.S.C. § 1406(a).
Following transfer, the court granted plaintiffs’ first motion for leave to amend their
complaint. After several attempts to amend their pleading, the court allowed leave for plaintiffs

to file their second amended complaint1 on November 28, 2018. Plaintiffs alleged defendants are
liable for breach of contract, unjust enrichment, fraud, and tortious interference with contract.
Two weeks after plaintiffs filed their complaint, defendant Merz North America, Inc.
(“Merz NA”) filed its motion to dismiss for failure to state a claim upon which relief can be
granted, seeking dismissal of plaintiffs’ complaint in its entirety. Defendant Merz Pharma GMBH
KGAA (“Merz Pharma”) joined defendant Merz NA’s motion. On September 26, 2019, the court
granted defendants’ motion to dismiss, holding that each of plaintiffs’ causes of action failed to
state a claim upon which relief can be granted.2
After entry of judgment, plaintiffs timely filed the instant motion. Plaintiffs do not seek to
amend the allegations in their complaint, and they do not seek to revive their fraud or tortious
interference with contract claims. Plaintiffs solely ask the court to vacate its judgment to allow
their breach of contract and unjust enrichment claims to proceed.
STATEMENT OF THE FACTS
The facts alleged in the complaint may be summarized as follows. During a conference
held from September 18, 2013, to September 21, 2013, in France, Michael Polakov (“Polakov”),
president of both plaintiffs in this action, met with Matthew Likens (“Likens”), then president and
chief executive officer of Ulthera, regarding the possibility of Ulthera being acquired by a
pharmaceutical company. (Compl. ¶¶ 11–13). Likens advised Polakov that although Ulthera had

1

Hereinafter, all references to the “complaint” in the text and to “Compl.” in citations are to the second
amended complaint filed November 28, 2018, (DE 189), unless otherwise specified.

2

The court also denied defendant Merz Pharma’s motion to dismiss for lack of personal jurisdiction, holding
that the court had specific personal jurisdiction arising from defendant Merz Pharma’s contacts with North Carolina.
The parties do not seek to amend or alter this portion of the court’s order.

2

expressed interest in being acquired to several companies, no substantive discussions or active
negotiations were ongoing. (Id. ¶¶ 13, 15). Thereafter, Likens and Polakov agreed at the
conference that plaintiffs had a nonexclusive engagement to market Ulthera to potential acquiring
companies in the pharmaceutical companies, and that plaintiffs would be entitled to a fee
commensurate with a standard industry fee ranging from one to five percent of the acquisition
price. (Id. ¶¶ 14, 16). Likens and Polakov shook hands to confirm their oral agreement. (Id. ¶
17).
Prior to meeting Likens, plaintiffs had prepared and maintained extensive confidential and
proprietary analysis of the medical aesthetics industry, including Ulthera, with which Polakov had
maintained a relationship for nearly a decade. (Id. ¶ 18). Both before and following discussion
with Likens, Polakov performed an extensive analysis of the synergies and market potential of
Ulthera for prospective acquirers. (Id. ¶¶ 19, 20).
A few days after Polakov’s discussion with Likens, he spoke with Jean-Yves Coste
(“Coste”), the healthcare director of Michel Dyens & Co. (“Michel Dyens”), an investment
banking company that represents acquirers within the healthcare and cosmetic medical field. (Id.
¶ 21). Coste indicated defendant Merz Pharma was interested in acquiring a company, and together
plaintiffs and Michel Dyens agreed to provide defendants with various targets for acquisition. (Id.
¶ 22). Plaintiffs provided Coste with Polakov’s detailed personal opinions, along with proprietary
and confidential analysis, on several acquisition companies, including Ulthera. (Id. ¶¶ 23, 24).
On September 26, 2013, Coste sent his initial email to Hans-Jorg Bergler (“Bergler”),
defendant Merz Pharma’s director of corporate development, providing a profile on Ulthera and
other companies. (Id. ¶ 25). Coste asked whether he would be interested in meeting with Likens.
3

(Id.). In October 2013, Ulthera and defendant Merz Pharma signed a non-disclosure agreement to
allow exchange of information, but no active negotiations with Ulthera occurred at any time in
2013. (Id. ¶¶ 26, 27). Coste engaged in further communications with Bergler and Philip Burchard
(“Burchard”), defendant Merz Pharma’s chief executive officer, including an October 30, 2013,
email where he again discussed possible target companies such as Ulthera. (Id. ¶ 28). Bergler
forwarded Coste’s email to Michael Parrish (“Parrish”), an employee of defendant Merz NA
recruited by defendant Merz Pharma to assist in acquisition efforts, and Parrish encouraged Bergler
to go forward with discussing the target companies with Coste by telephone on November 8, 2013.
(Id. ¶¶ 30–33).
Coste met with defendant Merz Pharma’s employees by phone on November 8, 2013. (Id.
¶¶ 36–37). At defendant Merz Pharma’s request, Coste sent plaintiffs’ private confidential and
written material regarding Ulthera and other potential target companies that had been discussed.
(Id. ¶¶ 38–39). Bergler then arranged to have Polakov and Coste travel to defendant Merz
Pharma’s headquarters in Frankfurt to make a business presentation and proposal regarding
acquiring companies including Ulthera. (Id. ¶ 40). In preparation for that meeting, Polakov
prepared an extensive presentation, including previous and new information from confidential and
proprietary sources on each of the acquisition targets that would be presented to defendants during
the meeting. (Id. ¶ 44).
On December 6, 2013, Polakov and Coste met with Bergler and Parrish, and Polakov
provided confidential information and analysis on each of the target companies. (Id. ¶¶ 45, 48).
Defendants allegedly agreed that, in exchange for information and analysis as well as applicable
merger and acquisition advisory services, plaintiffs would receive industry standard compensation
4

of between one to five percent of the acquisition price if defendant or any related entity purchased
any of the target companies. (Id. ¶¶ 48, 57, 61). Plaintiffs allege they were promised a guaranteed
one percent of the purchase price paid to acquire the target company, with the opportunity for that
percentage to be enhanced up to five percent in accordance with industry standards, to be paid by
defendant Merz NA or Merz Pharma or both. (Id. ¶¶ 49, 50, 60). During the meeting, Bergler and
Parrish asked specific and detailed questions about each of the prospective acquisition targets and
expressed concerns that Ulthera was not a good fit for defendants. (Id. ¶¶ 51, 52). In response,
Polakov gave an extensive and detailed proprietary presentation about how acquiring Ulthera
would be advantageous to defendants because investing in medical devices would produce
significant returns. (Id. ¶¶ 54, 55). After hearing Polakov’s explanation, Bergler and Parrish stated
they had been educated by Polakov as to these points and would reassess their views on Ulthera.
(Id. ¶ 56).
At the close of the meeting in December 2013, which Merz entity that might make the
acquisition was unknown, but Bergler and Parrish acknowledged the insightful and unique points
made by Polakov. (Id. ¶ 58). Plaintiffs allegedly would undertake merger and acquisition services
in connection with the Merz organization to the extent that defendants or a related entity went
forward with the merger. (Id. ¶ 61). Plaintiffs were to refine Polakov’s analysis of the companies
under discussion. (Id. ¶ 62).
On December 10, 2013, Coste sent a post-meeting email to Bergler and Parrish, recapping
the meeting. (Id. ¶ 64). Polakov also sent an email to Parrish thanking him for the meeting and
offering his assistance to Parrish. (Id. ¶ 65). On February 1, 2014, Burchard met with Coste at the
IMCAS Medical Conference in Paris. (Id. ¶ 68). During the meeting, Burchard advised Coste
5

that defendants were not interested in acquiring Ulthera, would not be moving forward to acquire
Ulthera, and would not be paying plaintiffs any fees pursuant to their agreement. (Id. ¶ 70). Coste
informed Polakov of defendants’ decision, and thereafter Polakov informed Likens that plaintiffs
were unable to obtain a potential buyer. (Id. ¶ 75).
Defendant Merz Pharma never informed plaintiffs that defendants had decided to
commence substantive discussions concerning a potential acquisition of Ulthera. (Id. ¶ 77).
However, despite statements made by Burchard, shortly thereafter Bergler and Parrish began to
negotiate with Ulthera regarding potential acquisition. (Id. ¶ 79). Defendants collaborated
extensively on negotiating and structuring a deal for the acquisition and integration of Ulthera.
(Id. ¶¶ 80–83). Ultimately, both Ulthera and Ultherapy, the process and procedure derived from
the acquisition of Ulthera, were incorporated into defendants’ business. (Id. ¶ 84).
Plaintiffs became aware of the acquisition of Ulthera by defendants for $600,000,000.00
in the summer of 2014. (Id. ¶ 85). Polakov and Coste approached Likens, who confirmed that
Ulthera did not engage in serious and substantive discussions with defndants regarding acquisition
until after the IMCAS Medical Conference in February 2014, a Merz entity acquired Ulthera, and
Likens thought Merz was responsible for paying all fees owed to plaintiffs. (Id. ¶¶ 88, 89).
Plaintiffs thereafter attempted to contact defendants to resolve the matter but were unsuccessful.
(Id. ¶¶ 87, 90–97). Defendant Merz Pharma’s in-house counsel claimed in an email on June 22,
2017, that defendants had commenced formal negotiations to acquire Ulthera in October 2013, and
further explained that defendants had adopted a mutual nondisclosure agreement with Ulthera prior
to being presented with Ulthera as a target company in September 2013. (Id. ¶ 98).
Additional facts pertinent to the instant motion will be discussed below.
6

COURT=S DISCUSSION
A.

Standard of Review
“A motion to alter or amend a judgment must be filed no later than 28 days after the entry

of the judgment.” Fed. R. Civ. P. 59(e). A motion to amend or alter a judgment is allowed only
“(1) to accommodate an intervening change in controlling law; (2) to account for new evidence
not available at trial; or (3) to correct a clear error of law or prevent manifest injustice.” Ingle ex
rel. Estate of Ingle v. Yelton, 439 F.3d 191, 197 (4th Cir. 2006) (internal citations omitted). “Rule
59(e), in essence, gives the district court a chance to correct its own mistake if it believes one has
been made.” Zinkand v. Brown, 478 F.3d 634, 637 (4th Cir. 2007). “Rule 59(e) motions may not
be used, however, to raise arguments which could have been raised prior to the issuance of the
judgment, nor may they be used to argue a case under a novel legal theory that the party had the
ability to address in the first instance.” Pac. Ins. Co. v. Am. Nat. Fire Ins. Co., 148 F.3d 396, 403
(4th Cir. 1998).
B.

Analysis
Plaintiffs do not seek to amend their pleading, and they do not raise any intervening change

in controlling law. Therefore, the court’s sole concern is whether allowing plaintiffs’ breach of
contract and unjust enrichment claims to proceed corrects a clear error of law or prevents a
manifest injustice.
1.

Breach of Contract

Plaintiffs argue that the court erred by finding no contract based on lack of mutual assent
and lack of a definite price term. The court turns its attention to the latter.

7

Under North Carolina law,3 the “elements of a claim for breach of contract are (1) existence
of a valid contract and (2) breach of the terms of that contract.” Crosby v. City of Gastonia, 635
F.3d 634, 645 (4th Cir. 2011) (quotations omitted). A contract, express or implied, requires mutual
assent, mutuality of promises, and definite terms. See Horton v. Humble Oil & Refining Co., 255
N.C. 675, 679 (1961). “For an agreement to constitute a valid contract, the parties ‘minds must
meet as to all the terms. If any portion of the proposed terms is not settled, or no mode agreed on
by which they may be settled, there is no agreement.’” Chappell v. Roth, 353 N.C. 690, 692 (2001)
(quoting Boyce v. McMahan, 285 N.C. 730, 734 (1974)). “To be binding, the terms of a contract
must be definite and certain or capable of being made so.” Horton, 255 N.C. at 679 (quoting
Williamson v. Miller, 231 N.C. 722, 728 (1950)).
Plaintiffs repeatedly alleged they were to receive one to five percent of the acquisition price
of any target company acquired by defendants or their affiliates. (See Compl. ¶¶ 16, 48–50, 110,
126, 131). In one part of the complaint, defendants allegedly agreed to a “guaranteed” one percent
of the acquisition price with up to five percent “based on the type and quality of the acquisition
deal ultimately arranged.” (Id. ¶ 48). Plaintiffs concede that any compensation exceeding one
percent is void for indefiniteness. (See Pl. Mem. (DE 242) at 5). However, plaintiffs argue that
the guaranteed one percent of the purchase price is severable, and thus enforceable. On this issue,
the court did not commit a clear error of law.
“A contract is entire, and not severable, when by its terms, nature and purpose it
contemplates and intends that each and all of its parts, material provisions, and the consideration,
are common each to the other and interdependent.” Mebane Lumber Co. v. Avery & Bullock
Builders, Inc., 270 N.C. 337, 341 (1967) (internal quotations omitted) (quoting Wooten v. Walters,

3

Both parties rely upon North Carolina law in support of their arguments on motion to dismiss.
Therefore, the court applies North Carolina law to the alleged contracts in this case.

8

110 N.C. 251, 254 (1892)). “Conversely, the hallmark of an installment contract is that its terms
contain two or more distinct items, both in the agreement to perform and in the promise of
compensation, capable of apportionment or separate allocation the one to the other, as indicated in
the contract itself.” Christenbury Eye Ctr., P.A. v. Medflow, Inc., 370 N.C. 1, 8 (2017) (internal
quotations omitted) (quoting Neal v. Wachovia Bank & Tr., 224 N.C. 103, 107 (1944)). A contract
is entire and indivisible when it “requir[es] full performance before anything is due.” Steamboat
Co. v. Transportation Co., 166 N.C. 582, 585 (1914).
In the instant case, the “guaranteed” one percent and the increase of up to five percent are
common to each other and interdependent. Stated differently, the face of plaintiffs’ complaint
indicates that the “guaranteed” one percent and the increase of up to five percent are tied to the
same consideration provided by plaintiffs: their confidential and proprietary analysis in support of
acquiring a prospective target company in the health industry. (See Compl. ¶¶ 16, 24, 48). As the
court previously put it, the complaint does not allege a series of separate deliverables to which the
court can separately attribute the one percent from the up to five percent. Therefore, the price term
is not divisible.
The case law cited by plaintiffs is in accord with the court’s analysis. In Kornegay v. Aspen
Asset Grp., LLC, the North Carolina Court of Appeals considered whether price terms were
divisible where plaintiff alleged “he was supposed to receive 20% of the profits from investment
projects he originated and implemented and would receive ‘fair’ compensation for implementing
investment projects that he did not originate.” 204 N.C. App. 213, 217 (2010). There, the court
found that “the two promises made . . . were in exchange for two distinct return promises by
plaintiff.” Id. at 227. Those promises were: “(1) 20% of profits in exchange for origination and
implementation of investment projects, and (2) fair treatment in exchange for implementation
efforts on projects plaintiff did not originate.” Id.
9

Plaintiffs attempt to analogize this case to Kornegay by arguing that the first promise was
that plaintiffs would be paid one percent of the purchase price in exchange for confidential
analysis. (Pl. Mem. (DE 242) at 6). Where plaintiffs’ argument breaks down is the supposedly
distinct second promise: that defendants agreed to pay plaintiffs up to an additional four percent
for different factors including advantageous terms and purchase price. (Pl. Mem. (DE 242) at 6).
Plaintiffs do not plausibly allege a separate and distinct “return promise” in exchange for this
variable four percent increase.
Plaintiffs’ reliance on George A. Fuller Co. v. Brown, 15 F.2d 672 (4th Cir. 1926) is equally
unpersuasive for the same reason. In that case, plaintiff was guaranteed at least $600.00 bonus
“on each of the succeeding hulls under the same conditions and in the same amounts provided the
profits earned warrant the same.” Id. at 676. As with Kornegay, the bonus earned was individually
attributable to each ship sold. See id. (emphasis added) (“[T]his same definite statement was either
expressly or impliedly made each time a bonus was paid plaintiff on the five succeeding ships.”).
Plaintiffs do not plausibly allege that the price for their services can be so apportioned. Therefore,
the court did not commit a clear error of law in dismissing plaintiffs’ breach of contract claim.
2.

Unjust Enrichment

Plaintiffs argue that the court erred by dismissing their unjust enrichment claim.
Quantum meruit, also known as unjust enrichment, “operates as an equitable remedy based
upon a quasi[-]contract or a contract implied in law which provides a measure of recovery for the
reasonable value of services rendered.” Ron Medlin Const. v. Harris, 364 N.C. 577, 580 (2010)
(internal quotations omitted) (quoting Whitfield v. Gilchrist, 348 N.C. 39, 42 (1998); Potter v.
Homestead Pres. Ass’n, 330 N.C. 569, 578 (1992)). Plaintiffs must 1) confer a benefit on
defendants, 2) the benefit must not have been conferred officiously or gratuitously, 3) the benefit

10

must be measurable, and 4) defendants must have consciously accepted the benefit. Booe v.
Shadrick, 322 N.C. 567, 570 (1988) (citing Wells v. Foreman, 236 N.C. 351 (1952)).
A benefit is given officiously when it is “conferred by an interference in the affairs of the
other party in a manner that is not justified in the circumstances.” Id. “Where a person has
officiously conferred a benefit upon another, the other is enriched but is not considered to be
unjustly enriched. The recipient of a benefit voluntarily bestowed without solicitation or
inducement is not liable for their value.” Wright v. Wright, 305 N.C. 345, 350 (1982) (quoting
Rhyne v. Sheppard, 224 N.C. 734, 737 (1944)).
Under North Carolina law, a measurable benefit is “the difference between the reasonable
value of the services rendered and the reasonable value of the benefits received.” Gales v. Smith,
251 N.C. 692, 693 (1960). Where the only issue underlying a quantum meruit claim is whether a
benefit is measurable, plaintiffs “would be entitled to nominal damages at least. To recover more,
plaintiff must prove the value of the services rendered.” Johnson v. Sanders, 260 N.C. 291, 295
(1963); see Harrell v. W. B. Lloyd Const. Co., 300 N.C. 353, 357 (1980). Allegations of
reasonable value must not be speculative. See Booe, 322 N.C. at 570–71.
On reconsideration, plaintiffs plausibly allege that at least some of the confidential and
proprietary information provided to defendants was a benefit not given officiously or gratuitously,
and that defendants consciously accepted that benefit. After receiving plaintiffs’ confidential
information, Parrish encouraged Bergler to go forward with discussing the target companies with
Coste by telephone on November 8, 2013. (Compl. ¶¶ 30–33). At defendant Merz Pharma’s
request, Coste sent plaintiffs’ private confidential and written material on potential target
companies that had been discussed over the phone. (Id. ¶¶ 38–39). Bergler then arranged for
Polakov and Coste to travel to defendant Merz Pharma’s headquarters in Frankfurt to make a
business presentation and proposal regarding acquiring companies including Ulthera. (Id. ¶¶ 40).
11

Finally, defendants were active participants in the presentation, soliciting information from
Polakov on the various companies. (See id. ¶¶ 53–56). The fact that defendants allegedly arranged
and actively engaged in the December 6, 2013, meeting allows a reasonable inference that
plaintiffs were not interfering with defendants’ affairs in an unjustified manner by providing
confidential and proprietary information on December 6, 2013. Moreover, although the parties
never agreed on an enforceable price term, supra, plaintiffs plausibly allege that the confidential
and proprietary information given at the meeting was provided with expectation of compensation.
(See Compl. ¶ 42).
Defendants previously argued that plaintiffs’ claim should be dismissed because plaintiffs
did not allege a measurable benefit.

See, e.g., Lake Toxaway Cmty. Ass’n, Inc. v. RYF

Enterprises, LLC, 226 N.C. App. 483, 490–91 (2013); Primerica Life Ins. Co. v. James Massengill
& Sons Const. Co., 211 N.C. App. 252, 260 (2011); Progressive Am. Ins. Co. v. State Farm Mut.
Auto. Ins. Co., 184 N.C. App. 688, 697 (2007). Even assuming defendants are correct that the one
to five percent figure alleged in the complaint is too speculative to state a claim for the reasonable
value of plaintiffs’ confidential and proprietary information,4 plaintiffs would still be entitled to
nominal damages. See Johnson, 260 N.C. at 295.
To correct a clear error of law and prevent manifest injustice in the instant action, the court
vacates its judgment and allows plaintiffs’ unjust enrichment claim to proceed to discovery.
CONCLUSION
Based on the foregoing, plaintiffs’ motion to amend or alter the judgment (DE 241) is
GRANTED IN PART and DENIED IN PART. The court VACATES its judgment and DIRECTS
the clerk to reopen this case. Plaintiffs’ claim for unjust enrichment is ALLOWED to proceed to

4

The court leaves for ruling on a more complete record the question of what counts as “reasonable value” for
services provided by plaintiffs.

12

discovery. Plaintiffs’ remaining causes of action are DISMISSED. Defendants’ motion for bill
of costs (DE 237) is DENIED AS MOOT. The court’s initial order on planning and scheduling
will follow.
SO ORDERED, this the 8th day of January, 2020.

_____________________________
LOUISE W. FLANAGAN
United States District Judge

13